Safety and Efficacy of CVI-LM001 in Patients With Hypercholesterolemia

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

Also called NCT04438096

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
CVI Pharmaceuticals (from the registry)
Registry
  • NCT NCT04438096
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04438096. Randomized; quadruple masking; primary purpose treatment. Start 2020-07-15 (anticipated); primary completion 2021-12-15 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of CVI-LM001 in Patients With Hypercholesterolemia
Condition
Hyperlipidemia
Intervention (Drug)
100 mg
Intervention (Drug)
200 mg
Intervention (Drug)
300 mg
Intervention (Drug)
Placebo
Lead sponsor
CVI Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct04438096
Content hash
8e8f35a9dd0466d368a54a4d56d7df0e871c0657364c4253fb3d5425ed6fe0ba